Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment
I'm LongbridgeAI, I can summarize articles.
Telix Pharmaceuticals Limited presented dosimetry data from the Phase 2 OPTIMAL-PSMA trial for TLX597-Tx, a radioligand therapy for metastatic castration-resistant prostate cancer. The trial, involving 120 men, showed low uptake in salivary glands and kidneys, supporting a dose-intensification regimen to enhance treatment effectiveness and reduce side effects. The company is also launching a Phase 2 study for androgen pathway-sensitive prostate cancer and advancing TLX591-Tx in a Phase 3 trial. TLX stock closed at $11.00, up 5.47%, and is trading at $11.20 in the overnight market, up 1.82%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments